Reperfusion After Thrombolytic Therapy in Ischemic Stroke Measured by Single‐Photon Emission Computed Tomography

Background and Purpose We used 99mTc-hexamethylpropyleneamine oxime single-photon emission computed tomography (SPECT) to study cerebral perfusion in patients treated with streptokinase for acute ischemic stroke in an open and prospective study. Our primary aims were (1) to compare the extent of reperfusion between patients who had received thrombolytic therapy and a control group studied during the same period who were ineligible to receive such therapy and (2) to determine if, among all patients, reperfusion led to improved outcome. Methods Fifty-seven patients (22 treated with streptokinase) had two SPECT studies performed, the first before streptokinase administration and the second 24 hours later. Results On the first SPECT study hypoperfusion was present in the middle cerebral artery or anterior cerebral artery territories in 40 patients (17 treated with streptokinase). Patients in the treatment and control groups with initial hypoperfusion on SPECT were well matched for the volume of the perfusion defect and the severity of neurological deficit. A greater number of patients who received streptokinase developed at least partial reperfusion (streptokinase, 65%; control, 52%) on the second study but not significantly so (P=.43). Similarly, the proportion of each hypoperfused region that reperfused (P=.74) and the reduction in the size of the perfusion defect (P =.06) were higher in the streptokinase group but did not reach statistical significance. When all patients were considered, those who did not reperfuse had higher mortality rates (P=.008), less neurological improvement (P=.016), and more functional disability (P < .001) than patients who had reperfusion or normal perfusion initially. Conclusions These findings suggest that at least some reperfusion during the first 48 hours of ischemic stroke is a common natural occurrence and is of prognostic significance. The observed trend toward better reperfusion indexes among patients treated with streptokinase is encouraging, but larger controlled trials are required to answer this definitively.

[1]  B. Siesjö,et al.  Thresholds in cerebral ischemia - the ischemic penumbra. , 1981, Stroke.

[2]  T. Olsen,et al.  A Dynamic Concept of Middle Cerebral Artery Occlusion and Cerebral Infarction in the Acute State Based on Interpreting Severe Hyperemia as a Sign of Embolic Migration , 1984, Stroke.

[3]  R. Crowell,et al.  Selective Necrosis and Total Necrosis in Focal Cerebral ischemia. Neuropathologic Observations on Experimental Middle Cerebral Artery Occlusion in the Macaque Monkey , 1984, Journal of neuropathology and experimental neurology.

[4]  P F Sharp,et al.  Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  W Lang,et al.  Initial experience with technetium-99m HM-PAO brain SPECT. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Alan C. Evans,et al.  The effect of spontaneous reperfusion on metabolic function in early human cerebral infarcts , 1987, Annals of neurology.

[7]  S. Hasselbalch,et al.  Quantitative Measurements of Cerebral Blood Flow Using SPECT and [99mTc]-d,l-HM-PAO Compared to Xenon-133 , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  G. Lenzi,et al.  Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours , 1989, Journal of the Neurological Sciences.

[9]  M. Fujishima,et al.  Hemorrhagic transformation in cerebral embolism. , 1989, Stroke.

[10]  V Hachinski,et al.  The Canadian Neurological Scale , 1989, Neurology.

[11]  J. Mountz,et al.  Prognostication of recovery following stroke using the comparison of CT and technetium-99m HM-PAO SPECT. , 1990, Journal of Nuclear Medicine.

[12]  M. Limburg,et al.  Thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: evaluation with rCBF‐SPECT , 1991, Acta neurologica Scandinavica.

[13]  J. Marler,et al.  Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.

[14]  A. Yamadori,et al.  Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke , 1992, Neurology.

[15]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.

[16]  Transcranial Doppler Sonography Monitoring of Local Intra‐arterial Thrombolysis in Acute Occlusion of the Middle Cerebral Artery , 1992, Stroke.

[17]  C. Weiller,et al.  Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization , 1992, Neurology.

[18]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[19]  Intra‐arterial streptokinase in acute ischaemic stroke; A pilot study , 1993, The Medical journal of Australia.

[20]  G. Marchal,et al.  PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome , 1993, The Lancet.

[21]  N. Lassen,et al.  Hyperfixation of HMPAO in subacute ischemic stroke leading to spuriously high estimates of cerebral blood flow by SPECT. , 1993, Stroke.